CD4CAR for CD4+ Leukemia and Lymphoma (NCT03829540)
A Phase I, Multicenter Study of CD4- Directed Chimeric Antigen Receptor Engineered T-cells (CD4CAR) in Patients With Relapsed or Refractory CD4+ Hematological Malignancies
🩺 Plain-English Summary (8th-Grade Level)
This study is designed as a single arm open label Phase I, 3x3, multicenter study of CD4-directed chimeric antigen receptor engineered T-cells (CD4CAR) in patients with relapsed or refractory T-cell leukemia and lymphoma. Specifically, the study will evaluate the safety and feasibility of CD4CAR T-cells. Funding Source - FDA OOPD
Who can join: Review the eligibility criteria below.
Location: University of Miami Sylvester Comprehensive Cancer Center — Miami, Florida
Age range: 12 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (6 Sites)
- University of Miami Sylvester Comprehensive Cancer Center — Miami, Florida
- Indiana University Melvin and Bren Simon Comprehensive Cancer Center — Indianapolis, Indiana
- Riley Hospital for Children — Indianapolis, Indiana
- Albert Einstein Health Network — New York, New York
- Stony Brook Cancer Center — Stony Brook, New York
- The University of Texas MD Anderson Cancer Center — Houston, Texas
📞 Contact the Study Coordinator
Phone: (317) 278-4184
Email: tnhaney@iu.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in T-cell Lymphoma
- A Study of Enasidenib in People With T-Cell Lymphoma — Basking Ridge, New Jersey
- A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma — Palo Alto, California
- Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma — New Haven, Connecticut
- A Registry for People With T-cell Lymphoma — Duarte, California
- Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma — Columbus, Ohio
Explore by condition: All T-cell Lymphoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.